Published in Leuk Lymphoma on June 12, 2013
Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep (2015) 0.93
Iron and cancer: recent insights. Ann N Y Acad Sci (2016) 0.86
Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. Cancer Sci (2014) 0.80
Anemia in lymphoma: interleukin-6, hepcidin and erythropoietin. Leuk Lymphoma (2013) 0.79
Iron deficiency or anemia of inflammation? : Differential diagnosis and mechanisms of anemia of inflammation. Wien Med Wochenschr (2016) 0.75
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Many sequence variants affecting diversity of adult human height. Nat Genet (2008) 12.80
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2007) 10.81
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2008) 7.65
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest (2005) 4.84
DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res (2002) 3.78
Afebrile Plasmodium falciparum parasitemia decreases absorption of fortification iron but does not affect systemic iron utilization: a double stable-isotope study in young Beninese women. Am J Clin Nutr (2010) 2.80
Hepcidin: from discovery to differential diagnosis. Haematologica (2008) 2.69
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.52
Tolerogenic dendritic cells: cytokine modulation comes of age. Blood (2006) 2.51
Profiling the humoral immune response in colon cancer patients: diagnostic antigens from Streptococcus bovis. Int J Cancer (2006) 2.50
Subcellular sites for bacterial protein export. Mol Microbiol (2004) 2.50
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica (2008) 2.46
Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem (2007) 2.41
Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum (2011) 2.38
Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest (2011) 2.36
Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J (2005) 2.33
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood (2007) 2.31
Towards the human colorectal cancer microbiome. PLoS One (2011) 2.30
Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One (2008) 2.13
Novel clues on the specific association of Streptococcus gallolyticus subsp gallolyticus with colorectal cancer. J Infect Dis (2011) 2.05
DNMT1-interacting RNAs block gene-specific DNA methylation. Nature (2013) 2.04
Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica (2009) 1.99
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. Acta Neurochir (Wien) (2012) 1.99
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica (2012) 1.98
ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood (2006) 1.95
Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica (2007) 1.95
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood (2005) 1.88
Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood (2011) 1.79
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma (2012) 1.77
Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood (2003) 1.76
Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood (2010) 1.75
Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis (2011) 1.74
The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease. Lancet Infect Dis (2013) 1.72
Rapid genotyping of single nucleotide polymorphisms using novel minor groove binding DNA oligonucleotides (MGB probes). Hum Mutat (2002) 1.70
Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem (2010) 1.68
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol (2010) 1.66
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol (2008) 1.64
Assessment of urinary concentrations of hepcidin provides novel insight into disturbances in iron homeostasis during malarial infection. J Infect Dis (2009) 1.63
Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood (2011) 1.62
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood (2006) 1.60
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica (2002) 1.60
Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood (2002) 1.57
Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica (2002) 1.56
Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts. Int J Cancer (2008) 1.55
Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. Haematologica (2008) 1.54
Regulation of hepcidin: insights from biochemical analyses on human serum samples. Blood Cells Mol Dis (2007) 1.51
Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica (2009) 1.51
Hepcidin in human iron disorders: diagnostic implications. Clin Chem (2011) 1.50
Mutations of the BIK gene in human peripheral B-cell lymphomas. Genes Chromosomes Cancer (2003) 1.50
Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia. Leuk Res (2006) 1.48
Thyroid function and prevalence of anti-thyroperoxidase antibodies in a population with borderline sufficient iodine intake: influences of age and sex. Clin Chem (2005) 1.48
Increased serum hepcidin and alterations in blood iron parameters associated with asymptomatic P. falciparum and P. vivax malaria. Haematologica (2010) 1.47
The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol (2006) 1.47
Novel urine hepcidin assay by mass spectrometry. Blood (2005) 1.46
Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. AIDS (2010) 1.45
Serum iron parameters, HFE C282Y genotype, and cognitive performance in older adults: results from the FACIT study. J Gerontol A Biol Sci Med Sci (2010) 1.45
Primary plasma cell leukemia followed by testicular plasmacytoma. Int J Hematol (2011) 1.44
Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood (2008) 1.43
[Myeloproliferative disorders due to the use of gasoline as a solvent: report of three cases]. Med Lav (2005) 1.42
Endothelial progenitor cells in HIV-positive patients: what are we talking about? J Acquir Immune Defic Syndr (2013) 1.42
Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol (2005) 1.40
Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia. Haematologica (2005) 1.40
Absence of hepcidin gene mutations in 10 Italian patients with primary iron overload. Haematologica (2002) 1.39
Intravascular large B cell lymphoma: when lymphoma is suspected but routine diagnostic work-up is negative. Leuk Lymphoma (2009) 1.37